Skip to main content
SpringerLink
Log in

Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors

  • Chapter
  • First Online:
Twenty Years of G-CSF

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The cost of cancer care in the United States continues to rise quickly, outpacing both inflation and the increases seen in other areas of medicine. As a result, oncology is receiving increasing scrutiny regarding the way in which resources are utilized. Statistics from the National Institute of Health (NIH) estimate that cancer accounted for >US$200 billion in direct costs in the United States during 2007 and studies estimated the impact of indirect costs such as lost productivity to be >US$900 billion as of 2000 [1–3]. During a period of health reform, increasing focus is being placed on controlling costs and supportive care in oncology is an important area of focus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cancer Trends Progress Report – 2009/2010 Update. National Cancer Institute, NIH, DHHS, Bethesda, MD April 2010; Available from: http://progressreport.cancer.gov

  2. Elting LS, Shih YC (2004) The economic burden of supportive care of cancer patients. Support Care Cancer 12:219–226

    Article  PubMed  Google Scholar 

  3. Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ (2008) Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 100:1755–1762

    Article  PubMed  Google Scholar 

  4. Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453

    Article  PubMed  CAS  Google Scholar 

  5. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205

    Article  PubMed  CAS  Google Scholar 

  6. Lyman GH (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 3:557–571

    PubMed  Google Scholar 

  7. Ozer H, Armitage JO, Bennett CL et al (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558–3585

    PubMed  CAS  Google Scholar 

  8. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

    Google Scholar 

  9. Greenberg D et al (2010) When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 102:82–88

    Article  PubMed  Google Scholar 

  10. Esser M, Brunner H (2003) Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. Pharmacoeconomics 21:1295–1313

    Article  PubMed  Google Scholar 

  11. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051

    PubMed  CAS  Google Scholar 

  12. Talcott JA, Siegal RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322

    PubMed  CAS  Google Scholar 

  13. Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560

    Article  PubMed  Google Scholar 

  14. Lyman G, Lalla A, Barron R, Dubois RW (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 25:401–411

    Article  PubMed  CAS  Google Scholar 

  15. Lyman GH, Lalla A, Barron R, Dubois RW (2009) Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 31:1092–1104

    Article  PubMed  Google Scholar 

  16. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266

    Article  PubMed  Google Scholar 

  17. Lyman GH, Kuderer NM, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857–1864

    Article  PubMed  CAS  Google Scholar 

  18. Cosler LE, Calhoun EA, Agboola O, Lyman GH (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488–494

    Article  PubMed  Google Scholar 

  19. Cosler LE, Eldar-Lissai A, Culakova E et al (2007) Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 25:343–351

    Article  PubMed  CAS  Google Scholar 

  20. Timmer-Bonte JN, Adang EM, Smit HJ et al (2006) Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 24:2991–2997

    Article  PubMed  CAS  Google Scholar 

  21. Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11:172–1179

    Article  PubMed  Google Scholar 

  22. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167

    Article  PubMed  CAS  Google Scholar 

  23. Lyman GH, Dale DC, Wolff DA et al (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28:2914–2924

    Article  PubMed  Google Scholar 

  24. Crawford J, Armitage J, Balducci L et al (2009) Myeloid growth factors. J Natl Compr Canc Netw 7:64–83

    PubMed  CAS  Google Scholar 

  25. Lyman GH, Kleiner JM (2007) Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy. J Natl Compr Canc Netw 5:217–228

    PubMed  CAS  Google Scholar 

  26. Crawford J, Dale DC, Kuderer NM et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6:109–118

    PubMed  Google Scholar 

  27. Lyman GH, Delgado DJ (2003) Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402–2409

    Article  PubMed  Google Scholar 

  28. Haithcox S, Ramnes C, Lee H, Lu J, Lyman GH (2003) The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2:2

    Article  PubMed  Google Scholar 

  29. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21:4524–4531

    Article  PubMed  Google Scholar 

  30. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311

    Article  PubMed  CAS  Google Scholar 

  31. Ramsey SD, Liu Z, Boer R et al (2009) Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 12:217–225

    Article  PubMed  Google Scholar 

  32. Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC (2008) Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 26:290–296

    Article  PubMed  Google Scholar 

  33. Liu Z, Doan QV, Malin J, Leonard R (2009) The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 7:193–205

    PubMed  Google Scholar 

  34. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170

    Article  PubMed  CAS  Google Scholar 

  35. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184

    Article  PubMed  CAS  Google Scholar 

  36. Timmer-Bonte JN, de Boo TM, Smith HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984

    Article  PubMed  CAS  Google Scholar 

  37. Skrlin A, Radic I, Schwinke D et al (2010) Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 38:557–566

    Article  PubMed  CAS  Google Scholar 

  38. Waller CF, Bronchud M, Mair S, Challand R (2010) Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:927–933

    Article  PubMed  CAS  Google Scholar 

  39. Jelkmann W (2010) Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol 85:771–780

    Article  PubMed  Google Scholar 

  40. Mellstedt H (2010) Implications of the development of biosimilars for cancer treatment. Future Oncol 6:1065–1067

    Article  PubMed  Google Scholar 

  41. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411–419

    Article  PubMed  CAS  Google Scholar 

  42. Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12:478–483

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Duke University and the Duke Cancer Institute, 2424 Erwin Road, Suite 205, 27705, Durham, NC, USA

    Bradford R. Hirsch

  2. Duke Cancer Institute, Duke University, 2424 Erwin Road, Suite 205, Durham, NC, 27705, USA

    Gary H. Lyman

Authors
  1. Bradford R. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary H. Lyman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary H. Lyman .

Editor information

Editors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, 91320, California, USA

    Graham Molineux

  2. MA Foote Associates, Par Five Court 4284, Westlake Village, 91362, California, USA

    MaryAnn Foote

  3. Amgen, Inc., One Amgen Center Dr. 1, Thousand Oaks, 91320, California, USA

    Tara Arvedson

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Hirsch, B.R., Lyman, G.H. (2012). Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_22

Download citation

Publish with us

Policies and ethics

Search

Navigation